We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunological Assays Correlated for Lupus Diagnosis

By LabMedica International staff writers
Posted on 29 Feb 2012
Two immunoassays have been used to detect autoantibodies to the ribosomal P proteins (Rib-P) which are a serologic marker for systemic lupus erythematosus (SLE). More...


Enzyme immunoassays and an indirect immunofluorescence test have been tested and compared in their ability to diagnose SLE and to see whether the results are interrelated.

Scientists at Dong-A University College of Medicine (Busan, Republic of Korea) collected serum samples from 91 SLE patients, 50 rheumatoid arthritis patients and 43 healthy subjects, between March 2009 and May 2010. A total of 184 samples were analyzed for anti-Rib-P antibodies using two immunoassays and an indirect immunofluorescence test (IIF) simultaneously. The IIF on HEp-2 cells was assayed using HEP-ANA test system (Medical & Biological Laboratories, MBL, Naka-ku, Japan) and anti-Rib-P antibodies by IIF were determined by the pattern with cytoplasmic and nucleolar staining.

Of 91 SLE patients, the positive rates of two immunoassays for anti-Rib-P antibodies were significantly higher than that of IIF. Eleven of 91 SLE patients showed simultaneous positivity in two immunoassays, but negativity in IIF. None of 93 control group subjects was positive for anti-Rib-P antibodies in two immunoassays and IIF. The two immunoassays used were the Quanta Lite Ribosome P enzyme-linked immunosorbent assay (ELISA) (Inova Diagnostics, San Diego, CA, USA) which uses synthetic ribosome P antigen and the EliA Rib-P (Phadia AB; Uppsala, Sweden) which uses human recombinant ribosomal P-proteins P0, P1, and P2.

The authors concluded that the sensitivity of immunofluorescence antibody tests (IFA) on HEp-2 cells is not optimal as a first-line screening test for detection of anti-Rib-P in SLE patients. Therefore, additional immunoassays are required to determine the presence of anti-Rib-P antibodies. The high titer of anti-Rib-P antibodies determined using immunoassays could also be demonstrated by IIF on HEp-2 cells. The discrepancy between immunoassays and IIF on HEp-2 cells for detection of anti-Rib-P antibodies may be explained by their titer. The study was published on March 15, 2012, in the journal Clinica Chimica Acta.

Related Links:
Dong-A University College of Medicine
Medical & Biological Laboratories
Inova Diagnostics



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.